GSKs Acquisition of Sirtris: Independence or Integration Harvard Case Solution & Analysis

The executive of the pharmaceutical company GSK must choose whether to integrate the newly acquired biotechnology firm, Sirtris. Moncef Slaoui, Global Head of GSK R & D, acquisition of Sirtris stood to gain access to its potentially revolutionary science. Slaoui must balance the need to recoup the cost of the shares after the payment of two times the award for Sirtris with his desire to keep Christoph Westphal, Sirtris co-founder and CEO, and other key people in the company. His desire to protect Sirtris by GSK and the size of the bureaucracy is the period when GSK began major changes in their R & D organizations, which are aimed at decentralization and the externalization of R & D, as well as reconstruction of the process of resource allocation for parallel more venture capital-based model. The case also explores the views of Christoph Westphal early integration issues and the impact of GSK has on Sirtris. May be used in conjunction with individual the case of, oriented on the business-model of Sirtris author. «Hide
on Toby Stewart, James Weber Source: Harvard Business School 20 pages. Publication date: April 21, 2009. Prod. #: 809 026-PDF-ENG

GSKs Acquisition of Sirtris: Independence or Integration Case Solution Other Similar Case Solutions like

GSKs Acquisition of Sirtris: Independence or Integration

Share This